Publicacions en què col·labora amb Jesús María Hernández Rivas (15)

2022

  1. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Journal of Clinical Oncology, Vol. 364

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2016

  1. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse

    Oncotarget, Vol. 7, Núm. 49, pp. 80664-80679

  2. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2014

  1. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

    Haematologica, Vol. 99, Núm. 8, pp. 1365-1372

2012

  1. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

    Leukemia, Vol. 26, Núm. 12, pp. 2521-2529

2009

  1. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome

    Leukemia, Vol. 23, Núm. 4, pp. 664-672

2007

  1. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis

    British Journal of Haematology, Vol. 136, Núm. 1, pp. 80-86

  2. Optimización del uso de Agentes estimulantes del Receptor de la Eritropoyetina (AREs) en pacientes con neoplasias hematológicas basado en el nivel de hemoglobina reticulocitaria

    Mapfre Medicina, Vol. 18, Núm. 4, pp. 284-291

2004

  1. Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to their cytogenetic abnormalities

    Leukemia Research, Vol. 28, Núm. 11, pp. 1181-1187

2002

  1. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial

    Haematologica, Vol. 87, Núm. 2, pp. 154-166

2001

  1. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate-risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL

    Haematologica, Vol. 86, Núm. 6, pp. 586-595

1999

  1. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARα gene rearrangements

    Haematologica, Vol. 84, Núm. 5, pp. 405-412

1998

  1. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89)

    Haematologica, Vol. 83, Núm. 3, pp. 222-230

1997

  1. Complete cytogenetic but not molecular remission in a patient with myeloid blast crisis of chronic myeloid leukemia treated with carboplatin and ARA-C

    Haematologica, Vol. 82, Núm. 5, pp. 604-605